Page 1337 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

2 References

previous and current intraoperative exposure to 50% oxygen. capecitabine is typical of that reported with 5-fluorouracil.
Eur J Anaesthesiol. January 1999;16(1):66-68. Ann Oncol. March 2002;13(3):484-485.
28. Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of 45. Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A.
inhaled nitric oxide in patients with acute respiratory distress Cardiac toxicity from systemic cancer therapy: a comprehensive
syndrome: results of a randomized phase II trial. Inhaled Nitric review. Prog Cardiovasc Dis. September-October 2010;53(2):
Oxide in ARDS Study Group. Critical Care Med. 1998;26(1): 94-104.
15-23. 46. Zver S, Zadnik V, Bunc M, Rogel P, Cernelc P, Kozelj M. Cardiac
29. Holley A, Cartner M, Lipman J. Acute respiratory distress in a toxicity of high-dose cyclophosphamide in patients with mul-
bleomycin primed patient: a new use for nitric oxide. Anaesth tiple myeloma undergoing autologous hematopoietic stem cell
Intensive Care. February 2007;35(1):86-90. transplantation. Int J Hematol. June 2007;85(5):408-414.
30. Shanholtz C. Acute life-threatening toxicity of cancer treatment. 47. Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, Jones
Crit Care Clin. July 2001;17(3):483-502. RB. Cardiac toxicity following high-dose cyclophosphamide,
31. Shahab N, Haider S, Doll DC. Vascular toxicity of antineoplastic cisplatin, and BCNU (STAMP-I) for breast cancer. Biol Blood
agents. Semin Oncol. February 2006;33(1):121-138. Marrow Transplant. 2000;6(2A):198-203.
32. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, 48. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med.
Noonan DM. Cardiotoxicity of anticancer drugs: the need for April 13, 1995;332(15):1004-1014.
cardio-oncology and cardio-oncological prevention. J Natl 49. Schrader C, Keussen C, Bewig B, von Freier A, Lins M.
Cancer Inst. January 6, 2010;102(1):14-25. Symptoms and signs of an acute myocardial ischemia caused
33. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopatho- by chemotherapy with Paclitaxel (Taxol) in a patient with meta-
logic analysis of adriamycin cardiotoxicity. Cancer. August 1973; static ovarian carcinoma. Eur J Med Res. November 16, 2005;
32(2):302-314. 10(11):498-501.
34. Geiger S, Lange V, Suhl P, Heinemann V, Stemmler HJ. Anticancer 50. Yeh ET, Bickford CL. Cardiovascular complications of cancer
therapy induced cardiotoxicity: review of the literature. Anticancer therapy: incidence, pathogenesis, diagnosis, and management.
Drugs. July 2010;21(6):578-590. J Am Coll Cardiol. June 16, 2009;53(24):2231-2247.
35. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for 51. Perez EA. Cardiac toxicity of ErbB2-targeted therapies: what do
doxorubicin-induced congestive heart failure. Ann Intern Med. we know? Clin Breast Cancer. March 2008;8(suppl 3):S114-S120.
November 1979;91(5):710-717. 52. Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in
36. Porembka DT, Lowder JN, Orlowski JP, Bastulli J, Lockrem J. cardiac development and function. Recent Prog Horm Res.
Etiology and management of doxorubicin cardiotoxicity. Crit 2004;59:1-12.
Care Med. June 1989;17(6):569-572. 53. Chaudhary P, Gajra A. Cardiovascular effects of EGFR (epider-
37. Hensley M, Hagerty K, Kewalramani T, et al. American Society mal growth factor receptor) monoclonal antibodies. Cardiovasc
of Clinical Oncology 2008 clinical practice guideline update: Hematol Agents Med Chem. July 2010;8(3):156-163.
use of chemotherapy and radiation therapy protectants. J Clin 54. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity
Oncol. 2009;27(1):127-145. associated with the cancer therapeutic agent sunitinib malate.
38. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Ann Oncol. September 2008;19(9):1613-1618.
Semin Oncol. February 2006;33(1):2-14. 55. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines
39. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 for the clinical use of cardiac radionuclide imaging—executive
update of recommendations for the use of chemotherapy and summary: a report of the American College of Cardiology/
radiotherapy protectants: clinical practice guidelines of the American Heart Association Task Force on Practice Guidelines
American Society of Clinical Oncology. J Clin Oncol. June 15, (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines
2002;20(12):2895-2903. for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll
40. Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin Cardiol. October 1, 2003;42(7):1318-1333.
(doxil): reduced clinical cardiotoxicity in patients reaching or 56. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment
exceeding cumulative doses of 500 mg/m . Ann Oncol. August of doxorubicin cardiotoxicity with quantitative radionuclide
2
2000;11(8):1029-1033. angiocardiography. N Engl J Med. 1979;300(6):278-283.
41. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of 57. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer
anthracycline agents for the treatment of cancer: systematic therapy-induced mucosal injury: pathogenesis, measurement,
review and meta-analysis of randomised controlled trials. BMC epidemiology, and consequences for patients. Cancer. May 1,
Cancer. 2010;10:337. 2004;100(9 suppl):1995-2025.
42. Ang C, Kornbluth M, Thirlwell MP, Rajan RD. Capecitabine- 58. Rogers BB. Mucositis in the oncology patient. Nurs Clin North
induced cardiotoxicity: case report and review of the literature. Am. December 2001;36(4):745-760, vii.
Curr Oncol. January 2010;17(1):59-63. 59. Peterson DE, Bensadoun RJ, Roila F. Management of oral and
43. Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated gastrointestinal mucositis: ESMO Clinical Practice Guidelines.
cardiotoxicity: revisited. Expert Opin Drug Saf. March 2009; Ann Oncol. May 2010;21(suppl 5):v261-v265.
8(2):191-202. 60. Keefe DM, Schubert MM, Elting LS, et al. Updated clinical
44. Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. practice guidelines for the prevention and treatment of mucositis.
Incidence of cardiotoxicity with the oral fluoropyrimidine Cancer. March 1, 2007;109(5):820-831.

Section07-O-ref.indd 2 1/21/2015 11:26:52 AM